This observational study, called PPD™ CorEvitas™ Psoriasis (PSO) Rapid Response, is looking at people with moderate to severe plaque psoriasis. It's not testing a new drug, but rather observing patients who are starting an "advanced therapy" for their psoriasis. The goal is to understand how patients respond to these treatments over 16 weeks, including their symptoms and how they feel. Researchers will collect information from you and your doctor at the start, and then at 2, 4, and 16 weeks after you begin your advanced therapy. You can join if you are at least 18 years old and have a diagnosis of moderate to severe plaque psoriasis. The study aims to enroll 2500 participants, but its current recruitment status is unclear.

Study design

This is an observational study, meaning researchers will collect information without giving you a specific treatment. It's a single-arm study, so everyone receives the same type of observation, and plans to include 2500 participants.

What's involved

You would have an in-person visit with your doctor at the start (Baseline), and then at 2, 4, and 16 weeks after you begin your advanced therapy. You will also complete study-specific questionnaires.

Compensation

Not stated in the trial record.

Follow-up

You will be followed for 16 weeks after starting your advanced therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.